Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    B3 Solutions Selected for JPEO Chem-Bio Defense Omnibus Support

    By Global Biodefense StaffMarch 20, 2013
    Share
    Facebook LinkedIn Reddit Email

    B3 Solutions, LLC. this week announced it has been awarded a prime position on the Acquisition Domain of the Omnibus Program Engineering and Technical Support contract supporting the development and fielding of chemical and biological defense materiel for the Department of Defense Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD).

    The five-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract expands B3 Solutions’ presence at JPEO-CBD. Including B3 Solutions, there are 22 awardees in the Acquisition Domain. All awardees have the potential to receive the full value amount of the IDIQ contract if all options are exercised.

    B3 Solutions will compete for JPEO-CBD task orders to provide acquisition, program management and relations management in CBD and national security communities, strategic planning, program analysis, life cycle management, international program analysis on foreign military sales, equipment expertise on the production and usage of CBD protective equipment, multimedia, graphics, technical writing support, and administrative support.

    “We look forward to providing the critical expertise required to help develop chemical and biological defense solutions,” said William Almas, B3 Solutions CEO. “Nothing is more important than keeping our armed forces and civilians out of harm’s way.”

    The JPEO-CBD is responsible for research, development and acquisition support of chemical, biological, radiological, and nuclear defense equipment and medical countermeasures for missions overseas and at home.

    Source: B3 Solutions 

    Awards JPEO-CBRND
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleAnthrax Vaccine Trial for Kids? The Ethics of Pediatric Countermeasures Research
    Next Article NHRC Provides Modeling Solutions for Joint Medical Planners

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023

    Smallpox Vaccines: Bavarian Nordic Awarded Another Contract to Supply EU Strategic Reserve

    September 13, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.